

# Luke S Howard

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8532347/publications.pdf>

Version: 2024-02-01

114  
papers

10,812  
citations

53789

45  
h-index

31843

101  
g-index

121  
all docs

121  
docs citations

121  
times ranked

11542  
citing authors

#	ARTICLE	IF	CITATIONS
1	Mendelian randomisation and experimental medicine approaches to interleukin-6 as a drug target in pulmonary arterial hypertension. <i>European Respiratory Journal</i> , 2022, 59, 2002463.	6.7	31
2	Incremental value of cardiopulmonary exercise testing in intermediate-risk pulmonary arterial hypertension. <i>Journal of Heart and Lung Transplantation</i> , 2022, 41, 780-790.	0.6	13
3	Autoimmunity Is a Significant Feature of Idiopathic Pulmonary Arterial Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2022, 206, 81-93.	5.6	9
4	BTS clinical statement for the assessment and management of respiratory problems in athletic individuals. <i>Thorax</i> , 2022, 77, 540-551.	5.6	2
5	ERS International Congress 2021: highlights from the Pulmonary Vascular Diseases Assembly. <i>ERJ Open Research</i> , 2022, 8, 00665-2021.	2.6	2
6	Bayesian Inference Associates Rare <i>KDR</i> Variants With Specific Phenotypes in Pulmonary Arterial Hypertension. <i>Circulation Genomic and Precision Medicine</i> , 2021, 14, .	3.6	29
7	EmPHasis-10 health-related quality of life score predicts outcomes in patients with idiopathic and connective tissue disease-associated pulmonary arterial hypertension: results from a UK multicentre study. <i>European Respiratory Journal</i> , 2021, 57, 2000124.	6.7	29
8	Plasma metabolomics exhibit response to therapy in chronic thromboembolic pulmonary hypertension. <i>European Respiratory Journal</i> , 2021, 57, 2003201.	6.7	25
9	Beyond the clot: perfusion imaging of the pulmonary vasculature after COVID-19. <i>Lancet Respiratory Medicine</i> , 2021, 9, 107-116.	10.7	119
10	Patterns of myocardial injury in recovered troponin-positive COVID-19 patients assessed by cardiovascular magnetic resonance. <i>European Heart Journal</i> , 2021, 42, 1866-1878.	2.2	274
11	Perioperative management of patients with pulmonary hypertension undergoing non-cardiothoracic, non-obstetric surgery: a systematic review and expert consensus statement. <i>British Journal of Anaesthesia</i> , 2021, 126, 774-790.	3.4	45
12	A diagnostic miRNA signature for pulmonary arterial hypertension using a consensus machine learning approach. <i>EBioMedicine</i> , 2021, 69, 103444.	6.1	30
13	Positioning imatinib for pulmonary arterial hypertension: A phase I/II design comprising dose finding and single-arm efficacy. <i>Pulmonary Circulation</i> , 2021, 11, 1-12.	1.7	5
14	TORREY, a Phase 2 study to evaluate the efficacy and safety of inhaled seralutinib for the treatment of pulmonary arterial hypertension. <i>Pulmonary Circulation</i> , 2021, 11, 1-7.	1.7	24
15	Biological heterogeneity in idiopathic pulmonary arterial hypertension identified through unsupervised transcriptomic profiling of whole blood. <i>Nature Communications</i> , 2021, 12, 7104.	12.8	21
16	Incremental value of cardiopulmonary exercise testing in intermediate-risk pulmonary arterial hypertension. <i>European Heart Journal Supplements</i> , 2021, 23, .	0.1	0
17	Global Right Heart Assessment with Speckle-Tracking Imaging Improves the Risk Prediction of a Validated Scoring System in Pulmonary Arterial Hypertension. <i>Journal of the American Society of Echocardiography</i> , 2020, 33, 1334-1344.e2.	2.8	14
18	Whole-Blood RNA Profiles Associated with Pulmonary Arterial Hypertension and Clinical Outcome. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020, 202, 586-594.	5.6	45

#	ARTICLE	IF	CITATIONS
19	Whole-genome sequencing of patients with rare diseases in a national health system. <i>Nature</i> , 2020, 583, 96-102.	27.8	338
20	Systemic Consequences of Pulmonary Hypertension and Right-Sided Heart Failure. <i>Circulation</i> , 2020, 141, 678-693.	1.6	139
21	Intravascular Ultrasound Pulmonary Artery Denervation to Treat Pulmonary Arterial Hypertension (TROPHY1). <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 989-999.	2.9	47
22	Idiopathic pulmonary arterial hypertension and coexisting lung disease: is this a new phenotype?. <i>Pulmonary Circulation</i> , 2020, 10, 1-8.	1.7	16
23	The ADAMTS13-VWF axis is dysregulated in chronic thromboembolic pulmonary hypertension. <i>European Respiratory Journal</i> , 2019, 53, 1801805.	6.7	31
24	Acute pulmonary embolism. <i>Clinical Medicine</i> , 2019, 19, 243-247.	1.9	22
25	Management of pulmonary arterial hypertension in patients aged over 65 years. <i>European Heart Journal Supplements</i> , 2019, 21, K29-K36.	0.1	9
26	Genetic determinants of risk in pulmonary arterial hypertension: international genome-wide association studies and meta-analysis. <i>Lancet Respiratory Medicine</i> , 2019, 7, 227-238.	10.7	122
27	ERS statement on exercise training and rehabilitation in patients with severe chronic pulmonary hypertension. <i>European Respiratory Journal</i> , 2019, 53, 1800332.	6.7	110
28	Reduced plasma levels of small HDL particles transporting fibrinolytic proteins in pulmonary arterial hypertension. <i>Thorax</i> , 2019, 74, 380-389.	5.6	34
29	The importance of patient perspectives in pulmonary hypertension. <i>European Respiratory Journal</i> , 2019, 53, 1801919.	6.7	85
30	Human PAH is characterized by a pattern of lipid-related insulin resistance. <i>JCI Insight</i> , 2019, 4, .	5.0	69
31	Lung Function, Inflammation, and Endothelin-1 in Congenital Heart Disease-Associated Pulmonary Arterial Hypertension. <i>Journal of the American Heart Association</i> , 2018, 7, .	3.7	17
32	Power of resting echocardiographic measurements to classify pulmonary hypertension patients according to European society of cardiology exercise testing risk stratification cut-offs. <i>International Journal of Cardiology</i> , 2018, 257, 291-297.	1.7	5
33	Identification of rare sequence variation underlying heritable pulmonary arterial hypertension. <i>Nature Communications</i> , 2018, 9, 1416.	12.8	279
34	Thrombolysis for PE: less is more?. <i>Thorax</i> , 2018, 73, 412-413.	5.6	2
35	Right ventriculoarterial uncoupling and impaired contractile reserve in obese patients with unexplained exercise intolerance. <i>European Journal of Applied Physiology</i> , 2018, 118, 1415-1426.	2.5	6
36	Non-vitamin K antagonist oral anticoagulants for pulmonary embolism: who, where and for how long?. <i>Expert Review of Respiratory Medicine</i> , 2018, 12, 387-402.	2.5	3

#	ARTICLE	IF	CITATIONS
37	Echocardiographic Screening for Pulmonary Hypertension in Congenital Heart Disease. <i>Journal of the American College of Cardiology</i> , 2018, 72, 2778-2788.	2.8	38
38	Is right heart catheterisation still a fundamental part of the follow-up assessment of pulmonary arterial hypertension? The argument against. <i>European Respiratory Journal</i> , 2018, 52, 1800996.	6.7	7
39	Echocardiographic assessment of pulmonary hypertension: a guideline protocol from the British Society of Echocardiography. <i>Echo Research and Practice</i> , 2018, 5, G11-G24.	2.5	174
40	British Thoracic Society Guideline for the initial outpatient management of pulmonary embolism. <i>BMJ Open Respiratory Research</i> , 2018, 5, e000281.	3.0	16
41	BTS guidelines for the initial outpatient management of pulmonary embolism: there's no place like home. <i>Thorax</i> , 2018, 73, 607-608.	5.6	5
42	Resting right ventricular function is associated with exercise performance in PAH, but not in CTEPH. <i>European Heart Journal Cardiovascular Imaging</i> , 2018, 19, 185-192.	1.2	12
43	Survival in portopulmonary hypertension: Outcomes of the United Kingdom National Pulmonary Arterial Hypertension Registry. <i>Journal of Heart and Lung Transplantation</i> , 2017, 36, 770-779.	0.6	73
44	Plasma proteome analysis in patients with pulmonary arterial hypertension: an observational cohort study. <i>Lancet Respiratory Medicine</i> , 2017, 5, 717-726.	10.7	99
45	Inhibition of pyruvate dehydrogenase kinase improves pulmonary arterial hypertension in genetically susceptible patients. <i>Science Translational Medicine</i> , 2017, 9, .	12.4	206
46	Exertional dyspnoea in pulmonary arterial hypertension. <i>European Respiratory Review</i> , 2017, 26, 170039.	7.1	25
47	Macitentan for the treatment of inoperable chronic thromboembolic pulmonary hypertension (MERIT-1): results from the multicentre, phase 2, randomised, double-blind, placebo-controlled study. <i>Lancet Respiratory Medicine</i> , 2017, 5, 785-794.	10.7	201
48	The CRASH report: emergency management dilemmas facing acute physicians in patients with pulmonary arterial hypertension. <i>Thorax</i> , 2017, 72, 1035-1045.	5.6	30
49	Plasma Metabolomics Implicates Modified Transfer RNAs and Altered Bioenergetics in the Outcomes of Pulmonary Arterial Hypertension. <i>Circulation</i> , 2017, 135, 460-475.	1.6	154
50	An official European Respiratory Society statement: pulmonary haemodynamics during exercise. <i>European Respiratory Journal</i> , 2017, 50, 1700578.	6.7	222
51	Patient engagement and self-management in pulmonary arterial hypertension. <i>European Respiratory Review</i> , 2016, 25, 399-407.	7.1	39
52	Exercise physiological responses to drug treatments in chronic thromboembolic pulmonary hypertension. <i>Journal of Applied Physiology</i> , 2016, 121, 623-628.	2.5	22
53	Dynamic Risk Stratification of Patient Long-Term Outcome After Pulmonary Endarterectomy. <i>Circulation</i> , 2016, 133, 1761-1771.	1.6	307
54	125â€¦Deterioration of Right Ventricular Function on Exercise Detected by Exercise Cardiac Magnetic Resonance Imaging in Patients with Pulmonary Arterial Hypertension. <i>Heart</i> , 2016, 102, A88-A89.	2.9	0

#	ARTICLE	IF	CITATIONS
55	Risk Stratification of Patients With Acute Symptomatic Pulmonary Embolism Based on Presence or Absence of Lower Extremity DVT. <i>Chest</i> , 2016, 149, 192-200.	0.8	76
56	Intravenous Iron Therapy in Patients with Idiopathic Pulmonary Arterial Hypertension and Iron Deficiency. <i>Pulmonary Circulation</i> , 2015, 5, 466-472.	1.7	79
57	Connective tissue disease-associated pulmonary arterial hypertension. <i>F1000prime Reports</i> , 2015, 7, 06.	5.9	41
58	Pulmonary arterial hypertension: the burden of disease and impact on quality of life. <i>European Respiratory Review</i> , 2015, 24, 621-629.	7.1	128
59	Left Main Bronchus Compression Due to Main Pulmonary Artery Dilatation in Pulmonary Hypertension: Two Case Reports. <i>Pulmonary Circulation</i> , 2015, 5, 723-725.	1.7	8
60	Pulmonary arterial hypertension exacerbated by ruxolitinib. <i>Haematologica</i> , 2015, 100, e244-e245.	3.5	37
61	Developments in the management and treatment of pulmonary embolism. <i>European Respiratory Review</i> , 2015, 24, 484-497.	7.1	20
62	Relating oxygen partial pressure, saturation and content: the haemoglobinâ€“oxygen dissociation curve. <i>Breathe</i> , 2015, 11, 194-201.	1.3	239
63	Abstract 202: The Role of Neutrophil Extracellular Traps in the Pathogenesis of Pulmonary Hypertension.. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2015, 35, .	2.4	0
64	Iron deficiency in systemic sclerosis patients with and without pulmonary hypertension. <i>Rheumatology</i> , 2014, 53, 285-292.	1.9	56
65	Thrombolytic therapy for submassive pulmonary embolus? PRO viewpoint. <i>Thorax</i> , 2014, 69, 103-105.	5.6	4
66	Physiciansâ€™ and patientsâ€™ expectations of therapies for pulmonary arterial hypertension: where do they meet?. <i>European Respiratory Review</i> , 2014, 23, 458-468.	7.1	12
67	Response to Pulmonary Arterial Hypertension Drug Therapies in Patients with Pulmonary Arterial Hypertension and Cardiovascular Risk Factors. <i>Pulmonary Circulation</i> , 2014, 4, 669-678.	1.7	21
68	Aberrant Chloride Intracellular Channel 4 Expression Contributes to Endothelial Dysfunction in Pulmonary Arterial Hypertension. <i>Circulation</i> , 2014, 129, 1770-1780.	1.6	63
69	Cardiopulmonary Exercise Testing Demonstrates Maintenance of Exercise Capacity in Patients With Hypoxemia and Pulmonary Arteriovenous Malformations. <i>Chest</i> , 2014, 146, 709-718.	0.8	24
70	NICE guideline: management of venous thromboembolic diseases and role of thrombophilia testing. <i>Thorax</i> , 2013, 68, 391-393.	5.6	53
71	Treatment Goals of Pulmonary Hypertension. <i>Journal of the American College of Cardiology</i> , 2013, 62, D73-D81.	2.8	250
72	Reduced MicroRNA-150 Is Associated with Poor Survival in Pulmonary Arterial Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2013, 187, 294-302.	5.6	153

#	ARTICLE	IF	CITATIONS
73	Understanding the impact of pulmonary arterial hypertension on patients' and carers' lives. <i>European Respiratory Review</i> , 2013, 22, 535-542.	7.1	120
74	Heterogeneity in Lung <sup>18</sup> F FDG Uptake in Pulmonary Arterial Hypertension. <i>Circulation</i> , 2013, 128, 1214-1224.	1.6	107
75	Last call for the flight simulation test?. <i>European Respiratory Journal</i> , 2013, 42, 1175-1177.	6.7	11
76	Authors'™ response to: How should we best determine the need for in-flight oxygen in patients with pulmonary arterial hypertension. <i>Thorax</i> , 2013, 68, 680.2-681.	5.6	0
77	The association between tricuspid regurgitation velocity and 5-year survival in a North West London population of patients with sickle cell disease in the United Kingdom. <i>British Journal of Haematology</i> , 2013, 162, 400-408.	2.5	28
78	Cardiopulmonary Exercise Testing. <i>Pulmonary Medicine</i> , 2012, 2012, 1-3.	1.9	0
79	An audit of hypoxaemia, hyperoxaemia, hypercapnia and acidosis in blood gas specimens. <i>European Respiratory Journal</i> , 2012, 39, 219-221.	6.7	6
80	Echocardiographic assessment of pulmonary hypertension: standard operating procedure. <i>European Respiratory Review</i> , 2012, 21, 239-248.	7.1	146
81	Changing Demographics, Epidemiology, and Survival of Incident Pulmonary Arterial Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2012, 186, 790-796.	5.6	483
82	Morphologic and Functional Remodeling of the Right Ventricle in Pulmonary Hypertension by Real Time Three Dimensional Echocardiography. <i>American Journal of Cardiology</i> , 2012, 109, 906-913.	1.6	47
83	Pulmonary vascular disease: pulmonary thromboembolism and pulmonary hypertension. <i>Medicine</i> , 2012, 40, 214-220.	0.4	1
84	How to assess the dangers of hyperoxemia: methodological issues. <i>Critical Care</i> , 2011, 15, 435.	5.8	2
85	Dexamethasone reverses monocrotaline-induced pulmonary arterial hypertension in rats. <i>European Respiratory Journal</i> , 2011, 37, 813-822.	6.7	85
86	Iron Deficiency and Raised Hcpidin in Idiopathic Pulmonary Arterial Hypertension. <i>Journal of the American College of Cardiology</i> , 2011, 58, 300-309.	2.8	208
87	British Thoracic Society emergency oxygen audits. <i>Thorax</i> , 2011, 66, 734-735.	5.6	48
88	Right atrial flutter isthmus ablation is feasible and results in acute clinical improvement in patients with persistent atrial flutter and severe pulmonary arterial hypertension. <i>International Journal of Cardiology</i> , 2011, 149, 279-280.	1.7	42
89	Outpatient management of pulmonary embolism. <i>Lancet, The</i> , 2011, 378, 5-6.	13.7	7
90	Differences in Ventilatory Inefficiency Between Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension. <i>Chest</i> , 2011, 140, 1284-1291.	0.8	93

#	ARTICLE	IF	CITATIONS
91	Combination therapy in pulmonary arterial hypertension: do we have the right strategy?. Expert Review of Respiratory Medicine, 2011, 5, 191-205.	2.5	6
92	Rebound hypoxaemia after administration of oxygen in an acute exacerbation of chronic obstructive pulmonary disease. BMJ: British Medical Journal, 2011, 342, d1557-d1557.	2.3	19
93	Iron deficiency in pulmonary arterial hypertension: a potential therapeutic target. European Respiratory Journal, 2011, 38, 1453-1460.	6.7	97
94	Prognostic factors in pulmonary arterial hypertension: assessing the course of the disease. European Respiratory Review, 2011, 20, 236-242.	7.1	67
95	Red cell distribution width outperforms other potential circulating biomarkers in predicting survival in idiopathic pulmonary arterial hypertension. Heart, 2011, 97, 1054-1060.	2.9	154
96	Safety of sapropterin dihydrochloride (6 $\alpha$ -BH <sub>4</sub> ) in patients with pulmonary hypertension. Experimental Lung Research, 2011, 37, 26-34.	1.2	49
97	Right ventricular function in patients with pulmonary hypertension; the value of myocardial performance index measured by tissue Doppler imaging. European Journal of Echocardiography, 2010, 11, 719-724.	2.3	29
98	Reduced Confounding by Impaired Ventilatory Function With Oxygen Uptake Efficiency Slope and VE/VCO <sub>2</sub> Slope Rather Than Peak Oxygen Consumption to Assess Exercise Physiology in Suspected Heart Failure. Congestive Heart Failure, 2010, 16, 259-264.	2.0	5
99	Maintain normoxaemia until more evidence is available. BMJ: British Medical Journal, 2010, 341, c3715-c3715.	2.3	6
100	Simvastatin as a Treatment for Pulmonary Hypertension Trial. American Journal of Respiratory and Critical Care Medicine, 2010, 181, 1106-1113.	5.6	112
101	Evidence of Dysfunction of Endothelial Progenitors in Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2009, 180, 780-787.	5.6	206
102	Oxygen therapy. Clinical Medicine, 2009, 9, 156-159.	1.9	7
103	Response to Letter Regarding Article, "Circulating Endothelial Progenitor Cells in Patients With Eisenmenger Syndrome and Idiopathic Pulmonary Arterial Hypertension". Circulation, 2009, 119, .	1.6	2
104	Guidelines for the diagnosis and treatment of pulmonary hypertension: The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). European Heart Journal, 2009, 30, 2493-2537.	2.2	3,108
105	Endothelin Receptor Antagonists for Pulmonary Arterial Hypertension. American Journal of Cardiovascular Drugs, 2008, 8, 171-185.	2.2	41
106	Circulating Endothelial Progenitor Cells in Patients With Eisenmenger Syndrome and Idiopathic Pulmonary Arterial Hypertension. Circulation, 2008, 117, 3020-3030.	1.6	208
107	Pulmonary veno-occlusive disease presenting with recurrent pulmonary oedema and the use of nitric oxide to predict response to sildenafil. Thorax, 2008, 63, 933-934.	5.6	34
108	Use of vasopressin after Caesarean section in idiopathic pulmonary arterial hypertension. British Journal of Anaesthesia, 2007, 99, 552-555.	3.4	67

#	ARTICLE	IF	CITATIONS
109	Emerging therapies for pulmonary arterial hypertension. <i>Expert Opinion on Investigational Drugs</i> , 2007, 16, 803-818.	4.1	14
110	Sirolimus-Induced Pulmonary Hypersensitivity Associated With a CD4 T-Cell Infiltrate. <i>Chest</i> , 2006, 129, 1718-1721.	0.8	38
111	Microbiological profile of community-acquired pneumonia in adults over the last 20 years. <i>Journal of Infection</i> , 2005, 50, 107-113.	3.3	61
112	Large granular lymphocyte leukaemia. <i>British Journal of Hospital Medicine (London, England: 2005)</i> , 2005, 66, 364-365.	0.5	3
113	Initial oxygen management in patients with an exacerbation of chronic obstructive pulmonary disease. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2005, 98, 499-504.	0.5	44
114	New therapeutic agents for pulmonary vascular disease. <i>Paediatric Respiratory Reviews</i> , 2005, 6, 285-291.	1.8	26